{"protocolSection":{"identificationModule":{"nctId":"NCT01766401","orgStudyIdInfo":{"id":"VLZ-MD-06"},"organization":{"fullName":"Forest Laboratories","class":"INDUSTRY"},"briefTitle":"Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder","officialTitle":"A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazadone in Patients With Generalized Anxiety Disorder","acronym":"VLZ-MD-06"},"statusModule":{"statusVerifiedDate":"2019-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-01-31","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-01-29","type":"ACTUAL"},"completionDateStruct":{"date":"2014-01-29","type":"ACTUAL"},"studyFirstSubmitDate":"2013-01-09","studyFirstSubmitQcDate":"2013-01-10","studyFirstPostDateStruct":{"date":"2013-01-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-12-04","resultsFirstSubmitQcDate":"2019-12-04","resultsFirstPostDateStruct":{"date":"2019-12-18","type":"ACTUAL"},"dispFirstSubmitDate":"2015-02-27","dispFirstSubmitQcDate":"2015-02-27","dispFirstPostDateStruct":{"date":"2015-03-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-12-04","lastUpdatePostDateStruct":{"date":"2019-12-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Forest Laboratories","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)."},"conditionsModule":{"conditions":["Generalized Anxiety Disorder"],"keywords":["Generalized Anxiety Disorder","GAD"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":402,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Matching placebo tablets, oral administration","interventionNames":["Drug: Placebo"]},{"label":"Vilazadone","type":"EXPERIMENTAL","description":"Vilazadone tablets, oral administration","interventionNames":["Drug: Vilazadone"]}],"interventions":[{"type":"DRUG","name":"Placebo","armGroupLabels":["Placebo"],"otherNames":["Dose-matched placebo tablets, oral administration, once per day"]},{"type":"DRUG","name":"Vilazadone","description":"Viibryd","armGroupLabels":["Vilazadone"],"otherNames":["Vilazadone once per day, 20 mg dose, oral administration or Vilazadone once per day, 40 mg dose, oral administration."]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score","description":"The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered scale which consists of 14 items, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The highest possible score is 56, which represents the most severe form of anxiety; the lowest possible score is 0, which represents an absence of anxiety.","timeFrame":"Baseline to Week 8"}],"secondaryOutcomes":[{"measure":"Change From Baseline in the Sheehan Disability Scale (SDS) Total Score","description":"The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe).","timeFrame":"Baseline to Week 8"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female, 18 - 70 Years of age\n* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Generalized Anxiety Disorder (GAD)\n* Minimum score of 20 on the Hamilton Rating Scale for Anxiety (HAM-A)\n\nExclusion Criteria:\n\n* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control\n* Patients with a history of meeting DSM-IV-TR criteria for:\n\n  * any manic, hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic, or mixed episode;\n  * any depressive episode with psychotic or catatonic features;\n  * panic disorder with or without agoraphobia;\n  * obsessive-compulsive disorder;\n  * Schizophrenia, schizoaffective, or other psychotic disorder;\n  * bulimia or anorexia nervosa;\n  * presence of borderline personality disorder or antisocial personality disorder;\n  * mental retardation, dementia, amnesia, or other cognitive disorders\n* Patients who are considered a suicide risk","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Giovanna Forero, MA","affiliation":"Forest Laboratories","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Forest Investigative Site 022","city":"Arcadia","state":"California","zip":"91007","country":"United States","geoPoint":{"lat":34.13973,"lon":-118.03534}},{"facility":"Forest Investigative Site 023","city":"Beverly Hills","state":"California","zip":"90210","country":"United States","geoPoint":{"lat":34.07362,"lon":-118.40036}},{"facility":"Forest Investigative Site 010","city":"Encino","state":"California","zip":"91316","country":"United States","geoPoint":{"lat":34.15917,"lon":-118.50119}},{"facility":"Forest Investigative Site 025","city":"Newport Beach","state":"California","zip":"92660","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"Forest Investigative Site 004","city":"Redlands","state":"California","zip":"92374","country":"United States","geoPoint":{"lat":34.05557,"lon":-117.18254}},{"facility":"Forest Investigative Site 007","city":"Sherman Oaks","state":"California","zip":"91403","country":"United States","geoPoint":{"lat":34.15112,"lon":-118.44925}},{"facility":"Forest Investigative Site 016","city":"Temecula","state":"California","zip":"92562","country":"United States","geoPoint":{"lat":33.49364,"lon":-117.14836}},{"facility":"Forest Investigative Site 012","city":"Upland","state":"California","zip":"91786","country":"United States","geoPoint":{"lat":34.09751,"lon":-117.64839}},{"facility":"Forest Investigative Site 017","city":"Coral Springs","state":"Florida","zip":"33067","country":"United States","geoPoint":{"lat":26.27119,"lon":-80.2706}},{"facility":"Forest Investigative Site 028","city":"Fort Myers","state":"Florida","zip":"33912","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Forest Investigative Site 002","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Forest Investigative Site 020","city":"Leesburg","state":"Florida","zip":"34748","country":"United States","geoPoint":{"lat":28.81082,"lon":-81.87786}},{"facility":"Forest Investigative Site 024","city":"Miami","state":"Florida","zip":"33015","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Forest Investigative Site 001","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Forest Investigative Site 026","city":"Indianapolis","state":"Indiana","zip":"46260","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Forest Investigative Site 029","city":"Shreveport","state":"Louisiana","zip":"71104","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Forest Investigative Site 019","city":"Las Vegas","state":"Nevada","zip":"89102","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Forest Investigative Site 003","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"Forest Investigative Site 031","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Forest Investigative Site 021","city":"Mason","state":"Ohio","zip":"45040","country":"United States","geoPoint":{"lat":39.36006,"lon":-84.30994}},{"facility":"Forest Investigative Site 030","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Forest Investigative Site 005","city":"Salem","state":"Oregon","zip":"97301","country":"United States","geoPoint":{"lat":44.9429,"lon":-123.0351}},{"facility":"Forest Investigative Site 014","city":"Allentown","state":"Pennsylvania","zip":"18104","country":"United States","geoPoint":{"lat":40.60843,"lon":-75.49018}},{"facility":"Forest Investigative Site 015","city":"Philadelphia","state":"Pennsylvania","zip":"19139","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Forest Investigative Site 027","city":"Lincoln","state":"Rhode Island","zip":"02865","country":"United States","geoPoint":{"lat":41.92111,"lon":-71.435}},{"facility":"Forest Investigative Site 006","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Forest Investigative Site 008","city":"Houston","state":"Texas","zip":"77054","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Forest Investigative Site 018","city":"Houston","state":"Texas","zip":"77096","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Forest Investigative Site 011","city":"Murray","state":"Utah","zip":"84123","country":"United States","geoPoint":{"lat":40.66689,"lon":-111.88799}},{"facility":"Forest Investigative Site 013","city":"Woodstock","state":"Vermont","zip":"05091","country":"United States","geoPoint":{"lat":43.62424,"lon":-72.51843}}]},"referencesModule":{"references":[{"pmid":"27486544","type":"DERIVED","citation":"Khan A, Durgam S, Tang X, Ruth A, Mathews M, Gommoll CP. Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. Prim Care Companion CNS Disord. 2016 Apr 28;18(2):10.4088/PCC.15m01904. doi: 10.4088/PCC.15m01904. eCollection 2016."},{"pmid":"26291335","type":"DERIVED","citation":"Gommoll C, Forero G, Mathews M, Nunez R, Tang X, Durgam S, Sambunaris A. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study. Int Clin Psychopharmacol. 2015 Nov;30(6):297-306. doi: 10.1097/YIC.0000000000000096."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Placebo","description":"Dose-matched placebo tablets, oral administration, once per day"},{"id":"FG001","title":"Vilazadone","description":"Vilazadone once per day, 20 mg dose, oral administration or Vilazadone once per day, 40 mg dose, oral administration."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"198"},{"groupId":"FG001","numSubjects":"200"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"161"},{"groupId":"FG001","numSubjects":"144"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"37"},{"groupId":"FG001","numSubjects":"56"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"22"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Safety Population consisted of all patients in the Randomized Population who took at least 1 dose of double-blind investigational product.","groups":[{"id":"BG000","title":"Placebo","description":"Dose-matched placebo tablets, oral administration, once per day"},{"id":"BG001","title":"Vilazadone","description":"Vilazadone once per day, 20 mg dose, oral administration or Vilazadone once per day, 40 mg dose, oral administration."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"198"},{"groupId":"BG001","value":"200"},{"groupId":"BG002","value":"398"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40.1","spread":"13.0"},{"groupId":"BG001","value":"40.5","spread":"13.2"},{"groupId":"BG002","value":"40.3","spread":"13.1"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"< 20","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"}]}]},{"title":"20-29","categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"98"}]}]},{"title":"30-39","categories":[{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"96"}]}]},{"title":"40-49","categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"81"}]}]},{"title":"50-59","categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"82"}]}]},{"title":"≥ 60","categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"33"}]}]}]},{"title":"Sex/Gender, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Male","categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"122"}]}]},{"title":"Female","categories":[{"measurements":[{"groupId":"BG000","value":"131"},{"groupId":"BG001","value":"145"},{"groupId":"BG002","value":"276"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"83"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"315"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"160"},{"groupId":"BG001","value":"164"},{"groupId":"BG002","value":"324"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"55"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"12"}]}]},{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score","description":"The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered scale which consists of 14 items, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The highest possible score is 56, which represents the most severe form of anxiety; the lowest possible score is 0, which represents an absence of anxiety.","populationDescription":"The Intent-to-Treat (ITT) Population consisted of all patients in the Safety Population who had at least 1 postbaseline assessment of the HAM-A.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on Scale","timeFrame":"Baseline to Week 8","groups":[{"id":"OG000","title":"Placebo","description":"Dose-matched placebo tablets, oral administration, once per day"},{"id":"OG001","title":"Vilazadone","description":"Vilazadone once per day, 20 mg dose, oral administration or Vilazadone once per day, 40 mg dose, oral administration."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":"7.37"},{"groupId":"OG001","value":"13.5","spread":"7.41"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0438","statisticalMethod":"MMRM","paramType":"Least Squares Mean Difference","paramValue":"-1.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.96","ciUpperLimit":"-0.04"}]},{"type":"SECONDARY","title":"Change From Baseline in the Sheehan Disability Scale (SDS) Total Score","description":"The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe).","populationDescription":"The Intent-to-Treat (ITT) Population consisted of all patients in the Safety Population who had at least 1 postbaseline assessment of the HAM-A.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on Scale","timeFrame":"Baseline to Week 8","groups":[{"id":"OG000","title":"Placebo","description":"Dose-matched placebo tablets, oral administration, once per day"},{"id":"OG001","title":"Vilazadone","description":"Vilazadone once per day, 20 mg dose, oral administration or Vilazadone once per day, 40 mg dose, oral administration."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"6.58"},{"groupId":"OG001","value":"7.8","spread":"6.91"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0868","statisticalMethod":"MMRM","paramType":"Least Squares Mean Difference","paramValue":"-1.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.02","ciUpperLimit":"0.20"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events were collected until week 8.","description":"The Safety Population consisted of all patients in the Randomized Population who took at least 1 dose of double-blind investigational product.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Dose-matched placebo tablets, oral administration, once per day","deathsNumAffected":0,"deathsNumAtRisk":198,"seriousNumAffected":0,"seriousNumAtRisk":198,"otherNumAffected":75,"otherNumAtRisk":198},{"id":"EG001","title":"Vilazadone","description":"Vilazadone once per day, 20 mg dose, oral administration or Vilazadone once per day, 40 mg dose, oral administration.","deathsNumAffected":0,"deathsNumAtRisk":200,"seriousNumAffected":0,"seriousNumAtRisk":200,"otherNumAffected":130,"otherNumAtRisk":200}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":198},{"groupId":"EG001","numAffected":63,"numAtRisk":200}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":198},{"groupId":"EG001","numAffected":62,"numAtRisk":200}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":198},{"groupId":"EG001","numAffected":13,"numAtRisk":198}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":198},{"groupId":"EG001","numAffected":11,"numAtRisk":200}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":198},{"groupId":"EG001","numAffected":9,"numAtRisk":200}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":198},{"groupId":"EG001","numAffected":15,"numAtRisk":200}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":198},{"groupId":"EG001","numAffected":15,"numAtRisk":200}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":198},{"groupId":"EG001","numAffected":12,"numAtRisk":200}]},{"term":"Abnormal dreams","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":198},{"groupId":"EG001","numAffected":10,"numAtRisk":200}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the PI will be subject to mutual agreement between the PI and Forest Research Institute, Inc."},"pointOfContact":{"title":"Therapeutic Area Head","organization":"Forest Research Institute, Inc","email":"IR-CTRegistration@allergan.com","phone":"877-277-8566"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D000098647","term":"Generalized Anxiety Disorder"}],"ancestors":[{"id":"D001008","term":"Anxiety Disorders"},{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000284","term":"Administration, Oral"}],"ancestors":[{"id":"D004333","term":"Drug Administration Routes"},{"id":"D004358","term":"Drug Therapy"},{"id":"D013812","term":"Therapeutics"}]}},"hasResults":true}